首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1542906

全球排卵症诊断市场 - 2024-2031

Global Ovulation Disorder Diagnosis Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

排卵障碍诊断市场规模

2023年，全球排卵症诊断市场规模达5.226亿美元，预计2031年将达到7.6899亿美元，2024-2031年预测期间复合年增长率为5.0%。

排卵障碍是女性或女孩不孕的主要原因。排卵障碍是女性月经週期中卵子生成的紊乱。这些疾病通常是由于下视丘功能障碍、卵巢早衰和多囊性卵巢症候群引起的。

排卵障碍诊断市场动态

排卵障碍诊断市场的成长是由于计划怀孕的增加、生育率的下降以及公众对不同排卵障碍的认识的提高而推动的

2型糖尿病患者多囊性卵巢症候群（PCOS）的盛行率预计将推动市场成长

多囊性卵巢症候群 (PCOS) 是一种常见的代谢和内分泌生殖疾病，与心血管、代谢和心理因素相关，影响全球约 7% 的女性。根据 2022 年 8 月发表在《内分泌学前沿》上的文章，糖尿病 (DM) 是全球公共卫生问题。到 2021 年，全球约有 5.37 亿成年人（20-79 岁）患有糖尿病，其中大多数是较年轻的年龄层。现在，越来越多的患者在年轻时患有第 2 型糖尿病 (T2DM)，而患有 T2DM 的女性在生育期更容易受到影响。女性 T2DM 患者的生殖功能障碍正在谨慎增加。与非T2DM患者相比，T2DM患者表现出更多的临床变化，如月经失调、多囊性卵巢等。这可能与黄体生成素和胰岛素协同作用引起的细胞雄性激素水平升高有关。

此外，PCOS是由2型糖尿病和高胰岛素中的内源性胰岛素抗性刺激卵巢颗粒细胞引起的，这会促进小卵泡的生长和数量。 PCOS 和 T2DM 具有生化、临床和代谢特征。 PCOS 或 T2DM 患者之间也存在很高的重迭率。 PCOS 涉及的 T2DM 可能会导致生殖系统的评估性损伤。越来越多的 PCOS 患者推动着市场。

公众意识的缺乏将阻碍市场的成长

然而，卫生专业人员和患者之间的先进知识差距导致了诊断延迟和护理变化。此外，缺乏针对受影响妇女的基于证据的、可获取的资讯导致了不满。许多女性不知道排卵，这会影响诊断资讯并导致不孕，并与各种健康风险相关。

COVID-19 影响分析

COVID-19的出现极大地影响了全球排卵症诊断市场。根据2020年7月发表在BMC Medicine上的文章，在育龄女性中，多囊性卵巢症候群（PCOS）是最常见的内分泌疾病，盛行率可能达到甚至超过10-15%。感染 COVID-19 的机会就越大。另一方面，由于交通限制和封锁，许多患者在大流行期间难以接受常规治疗。疫情期间，许多行业都处于停工状态，这对市场产生了负面影响。

不过，由于情况要到2022年中期而不是2021年才能扭转，病人现在可以在医院接受治疗。市场在预测期内也将呈现良好的成长。

排卵障碍诊断市场細項分析

预计多囊性卵巢症候群细分市场在预测期内（2024-2031）将以最快的复合年增长率成长

多囊性卵巢症候群预计将在预测期内提振市场。在某些情况下，女性无法产生足够的排卵所需的荷尔蒙。当不排卵时，卵巢会形成许多小囊肿。这些囊肿会产生称为雄性激素的荷尔蒙。患有多囊性卵巢综合症的女性通常雄激素水平较高。这会导致女性月经週期出现更多问题，并可能导致多囊性卵巢症候群的许多症状。如果有人月经不调，且血液检查显示雄性激素水平较高，则这些女性患有多囊性卵巢症候群。据克利夫兰诊所称，PCOS 非常常见。高达 15% 的育龄妇女患有此病。未诊断和治疗多囊性卵巢症候群的女性可能面临增加心血管疾病风险的风险，包括肥胖、高血压、怀孕糖尿病和高胆固醇。因此，诊断 PCOS 非常重要，PCOS 病例的增加导致诊断市场的需求不断增加。目前还没有专门诊断多囊性卵巢症候群 (PCOS) 的单一检查。医疗保健专业人员建议进行骨盆检查、血液检查和超音波检查。

排卵障碍诊断市场地域份额

北美地区占全球排卵症诊断市场最大份额

北美在排卵障碍诊断市场中占据主导地位，预计在预测期内将呈现类似的趋势。由于先进的医疗基础设施和公众对排卵障碍诊断的认识不断提高，预计在预测期内（2024-2031年）将保持巨大的市场规模。据美国疾病管制与预防中心称，PCOS 是导致女性不孕症的最常见原因之一，影响 6% 至 12%（多达 500 万）的美国育龄女性。多囊性卵巢症候群病例和女性健康意识的提高推动了北美地区的市场。此外，主要参与者正在采取合併和推出新产品等市场策略。例如，2021 年 12 月，Labcorp 收购了 Toxikon Corporation，这是一个提供一流非临床测试服务的合约研究组织。将 Toxikon 添加到 Labcorp 药物开发中将增强 Labcorp 强大的非临床开发产品组合。

排卵障碍诊断市场公司及竞争格局

排卵障碍诊断市场是本地和全球公司的适度竞争的市场。为市场成长做出贡献的一些主要参与者包括西门子医疗、通用电气医疗、富士胶片控股、瑞士精密诊断公司、东芝医疗系统公司、锐珂医疗、热那亚诊断、Quest Diagnostics、LabCorp 和 Esaote 等。主要参与者正在采取多种成长策略，例如治疗类型的推出、收购和合作，这有助于全球排卵障碍诊断市场的成长。

例如，

2022 年 7 月，佳能医疗系统美国公司收购了总部位于明尼苏达州明尼阿波利斯的医疗影像设备经销商和服务供应商 NXC Imaging。

东芝医疗系统公司 (TMSC)

概述：

TMSC 是一家製造、销售和提供医疗设备技术服务的公司，包括诊断 X 光系统、医用 X 光 CT 系统、磁振造影系统 (MRI)、电脑断层扫描 (CT) 诊断超音波系统、放射治疗系统等。

治疗类型组合：

电脑断层扫描：该系统在传统形态学的基础上，提供了功能诊断、动态观察等新的临床价值。还能够在 0.35 秒内旋转一圈提供 160 毫米宽的 3D 成像覆盖，并且扫描时间和曝光剂量更少，是患者友好的医疗护理。

全球排卵障碍诊断市场报告将提供约 65 个以上的市场资料表、65 个以上的数字以及 200 多个（大约）页数。

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10-15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Ovulation Disorder Diagnosis Market Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Ovulation Disorder Diagnosis Market Geographical Share

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2024-2031) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio.

Ovulation Disorder Diagnosis Market Companies and Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)

Overview:

TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet By Ovulation Disorders
3.2. Market Snippet By Diagnosis
3.3. Market Snippet By End-users
3.4. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising obesity rates
  - 4.1.1.2. The increasing prevalence of diabetes
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of awareness of diagnosis
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Ovulation Disorders

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 7.1.2. Market Attractiveness Index, By Ovulation Disorders
7.2. Polycystic Ovarian Syndrome*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Hyperprolactinemia
7.4. Luteal Phase Defect
7.5. Hypothalamus Dysfunction
7.6. Tumors
7.7. Autoimmune Oophoritis
7.8. Primary Ovarian Failure
7.9. Resistant Ovary Syndrome
7.10. Others

8. By Diagnosis

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 8.1.2. Market Attractiveness Index, By Diagnosis
8.2. Laboratory Testing of Hormones*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
8.4. Ovarian Biopsy
8.5. Others

9. By End-users

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 9.1.2. Market Attractiveness Index, By End-users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Gynecological Clinics
9.4. Diagnostic Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.4.6.
- 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Treatment type Benchmarking

12. Company Profiles

12.1. Siemens Healthcare*
- 12.1.1. Company Overview
- 12.1.2. Treatment type Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. GE Healthcare
12.3. Fujifilm Holdings
12.4. Swiss Precision Diagnostics
12.5. Toshiba Medical Systems Corporation
12.6. Carestream Health
12.7. Genova Diagnostics
12.8. Quest Diagnostics
12.9. LabCorp
12.10. Esaote(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球排卵症诊断市场 - 2024-2031